You have a patient on tirzepatide. She lost 22 pounds in four months. The dose is appropriate. She is doing everything you told her to do.

And then she stopped losing.

You increased the dose. Nothing happened. She is frustrated. You are frustrated. And the visit is starting to feel like a dead end.

Here is the truth: the medication did not fail. The clinical framework underneath it was incomplete from the beginning.

The Conventional GLP-1 Visit Is Missing the Metabolic Picture

When an NP is trained to manage GLP-1 therapy conventionally, the visit looks like this:

• Review weight and vitals
• Assess tolerability and side effects
• Titrate the dose based on response
• Counsel on diet and exercise
• Schedule follow-up

That is not wrong. It is just incomplete.

What that visit never asks is: what is happening in the metabolic environment underneath the medication? Because the GLP-1 receptor agonist improves the conditions for weight loss. It does not fix what was driving weight gain in the first place.

The Three Drivers Most NPs Never Assess

In the patient who plateaus, there are almost always three upstream drivers that the conventional visit never addresses.

1. Insulin resistance that predated the medication

Most GLP-1 patients have had insulin resistance for years before they ever filled the prescription. A fasting glucose of 98 and an A1c of 5.5 look fine on paper. They do not tell you what fasting insulin of 22 and a HOMA-IR of 4.7 tell you.

Insulin resistance at that level creates a metabolic environment where the body defends fat stores aggressively. The GLP-1 medication reduces appetite. It does not override that defense mechanism.

2. A cortisol pattern driving metabolic adaptation

Elevated morning cortisol is one of the most underassessed drivers of weight loss resistance. Cortisol drives gluconeogenesis, promotes fat storage in the visceral compartment, and triggers metabolic adaptation that works directly against every caloric deficit your patient is creating.

You cannot dose your way out of a cortisol problem.

3. A body composition picture that exercise is making worse

Cardio-dominant exercise in a caloric deficit breaks down lean mass. When your patient is losing muscle instead of fat, her resting metabolic rate drops, her insulin sensitivity worsens, and the plateau becomes self-reinforcing.

The exercise recommendation that came with the prescription was not wrong. It was not specific enough.

What to Add to Your GLP-1 Visit Right Now

You do not need to overhaul your practice to start seeing these patients differently. Add these three things to your next GLP-1 follow-up visit:

1. Fasting insulin and HOMA-IR. Optimal fasting insulin is 2 to 5 microunits per milliliter. Functional concern begins at 7 to 10. Above 15 is clinically significant. HOMA-IR is calculated as fasting insulin multiplied by fasting glucose divided by 405. Above 2.5 warrants direct intervention. Above 3.5 means insulin resistance is almost certainly driving the plateau.
2. Morning cortisol. A serum morning cortisol above 18 to 20 mcg/dL in the context of weight loss resistance warrants a direct clinical conversation about HPA axis dysregulation and its metabolic consequences.
3. A body composition assessment. Even a basic bioelectrical impedance measurement gives you lean mass versus fat mass data that changes the exercise prescription entirely. The goal is not weight loss. The goal is fat loss with lean mass preservation.

Two minutes added to your lab order. Three minutes added to your follow-up visit. A completely different clinical picture.

The Patient Who Does Not Plateau

The GLP-1 patient who continues to lose weight consistently is not just more compliant. Her fasting insulin is below 7. Her HOMA-IR is under 1.5. Her morning cortisol is within an optimal range. Her exercise prescription is building lean mass rather than breaking it down. That metabolic environment does not happen by accident. It is built by a clinician who knows how to look for it.

What This Means for Your Practice

The NPs who are getting the best outcomes with GLP-1 therapy are not the ones using the highest doses. They are the ones asking the next question after the standard visit is done.

What is happening in the metabolic environment underneath this medication?

That question is a clinical skill. It is built through a framework, not a single lab value or a single course.

If you want to see this framework applied to a real patient case, join me live on June 15 for a free clinical walkthrough. One patient. The complete metabolic picture. Exactly what I found when I looked underneath the conventional visit.

Register free here: https://www.bridgewelled.com/pl/2148788595

And if you are not ready for the live session, start with the BridgeWell Clinical Case Series: three real patient cases that show you what integrative clinical thinking looks like in practice.

Access the case series here: https://www.bridgewelled.com/case-series